CIK 0001106838
SONN Sonnet BioTherapeutics Holdings, Inc.
Insider trading from SEC Form 4. Last filing Dec 4, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at Sonnet BioTherapeutics Holdings, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 39 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 2, 2025 | Richard T Kenney Chief Medical Officer | DDisposition to issuer Common Stock | -9,374 | - | - | 0 | Dec 4, 2025 |
| Dec 2, 2025 | Richard T Kenney Chief Medical Officer | MOption exercise Common Stock | +86,505 | - | - | 86,505 | Dec 4, 2025 |
| Dec 2, 2025 | Richard T Kenney Chief Medical Officer | FTax withholding Common Stock | -16,891 | - | - | 69,614 | Dec 4, 2025 |
| Dec 2, 2025 | Richard T Kenney Chief Medical Officer | DDisposition to issuer Common Stock | -69,614 | - | - | 0 | Dec 4, 2025 |
| Dec 2, 2025 | Richard T Kenney Chief Medical Officer | MOption exercise Common Stock | +163,760 | - | - | 163,760 | Dec 4, 2025 |
| Dec 2, 2025 | Richard T Kenney Chief Medical Officer | DDisposition to issuer Common Stock | -163,760 | - | - | 0 | Dec 4, 2025 |
| Dec 2, 2025 | Richard T Kenney Chief Medical Officer | MOption exercise Warrant (Common Stock)derivative | -86,505 | - | - | 0 | Dec 4, 2025 |
| Dec 2, 2025 | Richard T Kenney Chief Medical Officer | DDisposition to issuer Warrant (Common Stock)derivative | -320,000 | - | - | 0 | Dec 4, 2025 |
| Dec 2, 2025 | Richard T Kenney Chief Medical Officer | MOption exercise Series 5 Preferred Stockderivative | -200 | - | - | 0 | Dec 4, 2025 |
| Dec 2, 2025 | John K. Cini Chief Scientific Officer | DDisposition to issuer Common Stock | -14,116 | - | - | 0 | Dec 3, 2025 |
| Dec 2, 2025 | Nailesh Bhatt director | DDisposition to issuer Common Stock | -10,547 | - | - | 0 | Dec 3, 2025 |
| Dec 2, 2025 | Raghu Rao Chief Executive Officer | DDisposition to issuer Common Stock | -22,356 | - | - | 0 | Dec 3, 2025 |
| Dec 2, 2025 | Lori McNeill director | DDisposition to issuer Common Stock | -4,394 | - | - | 0 | Dec 3, 2025 |
| Dec 2, 2025 | Stephen J McAndrew Chief Business Officer | DDisposition to issuer Common Stock | -6,446 | - | - | 0 | Dec 3, 2025 |
| Dec 2, 2025 | Donald J. Griffith Chief Financial Officer | DDisposition to issuer Common Stock | -10,375 | - | - | 0 | Dec 3, 2025 |
| Dec 2, 2025 | Albert D. Dyrness director | DDisposition to issuer Common Stock | -4,537 | - | - | 0 | Dec 3, 2025 |
| Dec 2, 2025 | Susan Dexter Chief Technical Officer | DDisposition to issuer Common Stock | -9,643 | - | - | 0 | Dec 3, 2025 |
| Jun 30, 2025 | Richard T Kenney Chief Medical Officer | AGrant or award Warrantderivative | +86,505 | - | - | 86,505 | Aug 21, 2025 |
| Jul 14, 2025 | Richard T Kenney Chief Medical Officer | AGrant or award Warrantderivative | +320,000 | - | - | 320,000 | Aug 21, 2025 |
| Jul 14, 2025 | Richard T Kenney Chief Medical Officer | AGrant or award Series 5 Preferred Stockderivative | +200 | - | - | 200 | Aug 21, 2025 |
| Jul 11, 2023 | Albert D. Dyrness director | AGrant or award Common Stock | +4,000 | - | - | 4,537 | Jul 15, 2025 |
| Jul 11, 2025 | Raghu Rao Interim CEO | AGrant or award Common Stock | +20,000 | - | - | 22,356 | Jul 15, 2025 |
| Jul 11, 2025 | Lori McNeill director | AGrant or award Common Stock | +4,000 | - | - | 4,394 | Jul 15, 2025 |
| Jul 11, 2025 | Stephen J McAndrew Chief Business Officer | AGrant or award Common Stock | +6,000 | - | - | 6,446 | Jul 15, 2025 |
| Jul 11, 2025 | Richard T Kenney Chief Medical Officer | AGrant or award Common Stock | +8,000 | - | - | 9,374 | Jul 15, 2025 |
| Jul 11, 2025 | Donald J. Griffith Chief Financial Officer | AGrant or award Common Stock | +10,000 | - | - | 10,375 | Jul 15, 2025 |
| Jul 11, 2025 | Susan Dexter Chief Technical Officer | AGrant or award Common Stock | +8,000 | - | - | 9,643 | Jul 15, 2025 |
| Jul 11, 2025 | John K. Cini Chief Scientific Officer | AGrant or award Common Stock | +12,000 | - | - | 14,116 | Jul 15, 2025 |
| Jul 11, 2025 | Nailesh Bhatt director | AGrant or award Common Stock | +10,000 | - | - | 10,547 | Jul 15, 2025 |
| Dec 11, 2023 | Nailesh Bhatt director | AGrant or award Common Stock | +373 | - | - | 547 | Dec 5, 2024 |
| Dec 11, 2023 | John K. Cini Chief Scientific Officer | AGrant or award Common Stock | +1,888 | - | - | 2,116 | Dec 5, 2024 |
| Dec 11, 2023 | John Harry Cross III Chief Financial Officer | AGrant or award Common Stock | -1,452 | - | - | 1,588 | Dec 5, 2024 |
| Dec 11, 2023 | Susan Dexter Chief Technical Officer | AGrant or award Common Stock | +1,452 | - | - | 1,643 | Dec 5, 2024 |
| Dec 11, 2023 | Albert D. Dyrness director | AGrant or award Common Stock | +373 | - | - | 537 | Dec 5, 2024 |
| Dec 11, 2023 | Donald J. Griffith Chief Financial Officer | AGrant or award Common Stock | +317 | - | - | 375 | Dec 5, 2024 |
| Dec 11, 2023 | Richard T Kenney Chief Medical Officer | AGrant or award Common Stock | +1,271 | - | - | 1,374 | Dec 5, 2024 |
| Dec 11, 2023 | Lori McNeill director | AGrant or award Common Stock | +373 | - | - | 394 | Dec 5, 2024 |
| Dec 11, 2023 | Pankaj Mohan Chairman, President and CEO | AGrant or award Common Stock | +7,554 | - | - | 14,987 | Dec 5, 2024 |
| Dec 11, 2023 | Raghu Rao Chief Executive Officer | AGrant or award Common Stock | +373 | - | - | 2,356 | Dec 5, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Nailesh Bhattdirector
- John K. CiniChief Scientific Officer
- John Harry Cross IIIChief Financial Officer
- Susan DexterChief Technical Officer
- Albert D. Dyrnessdirector
- Donald J. GriffithChief Financial Officer
- Richard T KenneyChief Medical Officer
- Stephen J McAndrewChief Business Officer
- Lori McNeilldirector
- Pankaj MohanChairman, President and CEO
- Raghu RaoChief Executive Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.